SCHEMBL17498168

SCHEMBL17498168

CS(=O)(=O)c1ccccc1S(=O)(=O)NC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.49
ITGAV P06756 1/20 0.48
PTGES O14684 1/20 0.44
ACLY P53396 1/20 0.43
LMNA P02545 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
ALKBH2 Q6NS38 1/20 0.40
ALKBH3 Q96Q83 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
CA9 Q16790 2/20 0.39
KAT6A Q92794 2/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206422 0.82 SLC1A3 (0.55) ITGAVLMNACA1CA2ALKBH2
Acetic Acid SCHEMBL28282471 0.80 ITGAV (0.42) BCAT2ITGAVPTGESACLYCA1
Biphenyl SCHEMBL9178383 0.78 SLC1A3 (0.51) ITGAVLMNACA1CA2MMP1
Cxl-1020 SCHEMBL1767680 0.78 CA1 (0.55) BCAT2ITGAVPTGESACLYCA1
SCHEMBL1925271 0.78 CA12 (0.51) BCAT2ITGAVCA1CA2CA9
SCHEMBL3954909 0.77 POLB (0.58) ITGAVCA1CA2SLC1A3SLC1A2
SCHEMBL6361993 0.77 POLB (0.53) PTGESCA1CA2MMP1MMP2
SCHEMBL10784100 0.77 POLB (0.58) ITGAVCA1CA2SLC1A3SLC1A2
SCHEMBL30296023 0.77 POLB (0.53) PTGESCA1CA2MMP1MMP2
SCHEMBL27176171 0.77 KAT6A (0.58) KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458127-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2016-10-04 US claimed
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES THE JOHNS HOPKINS UNIVERSITY 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 BCAT2 1590/4885ITGAV 4720/4885PTGES 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.